We Help Companies Find New Sales Opportunities
Alliance Pharma is to acquire the non-aesthetics business of London-based Sinclair IS Pharma for £132m.
Alliance Pharma has acquired MacuVision Europe, the Solihull-based supplier of eye care treatments, for an initial £5.5m.
Alliance Pharma has acquired the UK rights to the Lypsyl personal care brand from Novartis for £1.8m.
Alliance Pharma has acquired Opus Group Holdings, the distributor of skin creams and cleansers, for £8m.
Alliance Pharma has acquired three anti-malarial brands from AstraZeneca for an initial £4.2m.
Alliance Pharma has acquired the Quinoderm and Ceanel dermatology brands from Ferndale Pharmaceuticals for £1.5m.
Alliance Pharma has acquired the Ashton & Parsons teething treatment and Anbesol mouth ulcer brands from Reckitt Benckiser for £2.6m.
Alliance Pharma is to acquire the trade and assets of Cambridge Laboratories for up to £16m, with the transfer of about 30 staff in Newcastle and Dublin.
Alliance Pharma is to acquire the worldwide rights to the Buccastem and Timodine prescription brands from Reckitt Benckiser for £7.5m.
Alliance Pharma is to acquire Caraderm, the Northern Ireland-based developer of dermatological sprays, for £0.3m.
Alliance Pharma has raised £2.5m in a share placing to fund the development of its Chippenham-based pharmaceuticals business.
Alliance Pharma is to buy various pharmaceutical brands from Unigreg, as well as certain dental assets from CollaGenex International, for a combined £8.8m.
Alliance Pharma has acquired four Dermapharm dermatology brands for a total £0.9m, while the infrastructure and staff of Dermapharm which will be divested into a new company called Dermapharm Skincare.